Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

53404

Reuters

United Kingdom

Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial


In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Independent

Evgeny Lebedev

London

Greater London

England

Weight-loss drugs go head-to-head in new study. One was significantly more effective

The Woodbridge Company

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

Associated Press News

Independent Media

United States

Zepbound tops Wegovy for weight loss in Eli Lilly study

Study participants treated with Zepbound lost 20% of their body weight.

abc News

The Walt Disney Company

Zepbound leads to more weight loss than Wegovy, Eli Lilly says

New trial data has cemented Club holding Eli Lilly's pole position in the highly competitive weight loss drug race.

CNBC

Roberts family

Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their SURMOUNT-5 phase clinical trial on Wednesday which is the first time both GLP1s have been compared side-by-side.   Both drugs mimic the GLP-1 hormone to…

Zepbound brings more weight loss than Wegovy: Drugmaker

The Hill

Nexstar Media Group

Washington

District of Columbia

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

News World Communications

In new trial, Zepbound bests Wegovy for weight loss

According to the study, patients treated with Zepbound lost 47 percent more weight than those treated with the competing product Wegovy

Patienten, die mit Zepbound behandelt wurden, hätten laut der Studie 47 Prozent mehr Gewicht verloren als solche, die mit dem Konkurrenzprodukt Wegovy behandelt wurden

Lilly-Abnehmspritze Zepbound laut Studie effektiver als Wegovy

der Standard AT

Oscar Bronner

Vienna

Austria

Lilly weight loss injection Zepbound more effective than Wegovy according to study

Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study.
Zepbound achieved an average weight loss of 20.2% at 72 weeks in adults living with obesity without diabetes, com

MarketWatch

Murdoch family

Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal

(AP) — Shares of Eli Lilly & Company climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss. The study results should help …

WISH-TV

Indianapolis

Marion County

Indiana

Zepbound tops Wegovy for weight loss in Lilly study

Eli Lilly

Obesity

Research

Novo Nordisk

Health

Science

Medical

Wegovy

Fortune

Maariv Online

Time Magazine

Newswise

borsen.dk

Quartz

BizToc

Straight Arrow News

STAT

Morning News

World Today News

MedPage Today

Best Life

MedCity News

Stockxpo - A professional network of traders, investors and analysts

pipelinereview

Consenso del Mercado

reporter.am

avisendanmark.dk

elblog.pl

Dataemia

Endpoints News

Pharmaphorum

ramaonhealthcare.com

hcplive.com

Busines and Oil News

pharmaceutical-technology.com

Clinical Trials Arena

drugtopics.com

thenewsfront.com

bariatricnews.net

Drug Discovery and Development

Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial

Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics